Alcidion Group Limited Overview
Alcidion is an Australian-headquartered, UK-weighted health information technology vendor whose flagship Miya Precision platform delivers modular, interoperable clinical software to public hospitals and health systems in Australia, New Zealand and the United Kingdom. Rather than competing head-on with the monolithic "big-bang" electronic patient record (EPR) vendors, Alcidion has historically sold modules — patient flow, observations and assessments, clinical noting, clinical communications and tasking, command-centre visibility, emergency department and virtual care — that sit alongside or on top of incumbent systems. Since 2025 it has graduated into full EPR deployments for mid-sized NHS trusts (North Cumbria in February 2025 and University Hospitals Sussex in May 2026), positioning itself as a modern, cloud-native, modular EPR alternative to Oracle Health and Epic. FY26 revenue was A$51.6M (+27%), annual recurring revenue A$38.3M (+34%) and Underlying EBITDA A$6.8M, with A$20.6M cash and no borrowings.
Company's own description
In its FY26 results release (19 August 2026), Alcidion describes its purpose as transforming healthcare through proactive, smart and intuitive technology that lifts the efficiency and quality of patient care. It characterises its offer as a complementary set of software products and technical services built around Miya Precision, which aggregates information into centralised dashboards, supports interoperability, facilitates clinical and operational communication and task management, and provides clinical decision support at the point of care. The company states that it operates across three established markets — Australia, New Zealand and the United Kingdom — with further geographic expansion planned, and that it now serves over 400 hospitals and 87 healthcare organisations (FY25 AGM materials, October 2025).
Independent characterisation
Alcidion is best understood as a niche enterprise clinical-software vendor in transition from a module seller to a mid-market EPR platform provider. Three features define the business model:
-
Long-duration public-sector contracts. Customers are overwhelmingly government-funded hospitals (NHS trusts and health boards in the UK; state Local Health Districts/Networks and Hospital & Health Services in Australia; the Australian Defence Force via prime contractor Leidos). Contract terms of 5–10 years, often with extension options, are standard. The North Cumbria EPR is 10 years; UH Sussex is an initial 7 years; South Tees runs to 2033.
-
Revenue built on recurring product fees plus lumpy implementation and licence revenue. Recurring product revenue (support & maintenance, licence subscriptions, hosting) was A$31.9M in FY26 (≈62% of revenue). The balance is non-recurring: implementation services, technical services, upfront capital licence fees (e.g., ≈A$8.5M recognised in FY26 from UH Sussex) and third-party partner products resold where Alcidion acts as prime contractor.
-
High gross margins, operating leverage on a fixed cost base. Gross margin has run at 86–88% historically (80.3% in FY26 due to third-party product pass-through). Alcidion does not capitalise internal development costs (H1 FY25 results presentation), so R&D is fully expensed — a conservative policy that depresses reported profit relative to peers that capitalise.
Revenue model mix
| Revenue stream (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Recurring product revenue (S&M, licences, subscriptions, hosting) | 26.2 | 26.0 | 31.9 |
| Non-recurring revenue (implementation, services, upfront licences, third-party) — derived residual | 10.9 | 14.8 | 19.7 |
| Total revenue | 37.1 | 40.8 | 51.6 |
Source: FY25 results release (FY24 and FY25 recurring "Product – M&S + annual licences" A$26,197k and A$25,968k); FY26 results release (recurring A$31.9M, +23%). Non-recurring is derived as total less recurring. Note: FY23 results reported "recurring revenue" of A$28.1M (≈70% of revenue), which appears to use a broader definition than the FY24–FY26 series; the series are not strictly comparable. The FY24 AGM summary (Quartr) cited recurring revenue at 74% of FY24 revenue, versus 71% derived here — a definitional discrepancy noted.
Value-chain position
Alcidion sits in the application software layer of the hospital IT stack. It integrates with (rather than replaces) patient administration systems (PAS), laboratory and pharmacy systems, and incumbent EMRs from Oracle Health (Cerner) — East Lancashire and Alfred Health are cited integration reference sites (FY23 results) — while in EPR deals it becomes the system of record, supplemented by its own Silverlink PCS PAS and by third-party partners (e.g., Mizaic MediViewer electronic document management at North Cumbria). It also provides technical integration and data services inherited from MKM Health.
Customer types and end-markets
| Customer type | Examples (from company disclosures) | Market |
|---|---|---|
| NHS acute and integrated-care trusts (England) | North Cumbria Integrated Care, UH Sussex, South Tees, University Hospital Southampton, Dartford & Gravesham, Bolton, Lancashire Teaching, East Lancashire, Royal Wolverhampton, Moorfields Eye, Liverpool Heart & Chest | UK |
| NHS community trusts | Herefordshire & Worcestershire Health and Care | UK |
| Welsh health boards | Hywel Dda University Health Board | UK (Wales) |
| Australian state public health services | Alfred Health, Western Health, Peninsula Health, Hume Rural Health Alliance (Vic); NALHN (SA); Sydney LHD (NSW); NT Health; Gold Coast Health (Qld) | ANZ |
| Defence health | Australian Defence Force via Leidos Australia (Health Knowledge Management system) | ANZ |
| Private and public hospitals (via Kyra) | ≈33 Kyra customers, majority of Queensland Hospital & Health Services plus Vic, WA, Tas public/private | ANZ |
| New Zealand health providers | Via MKM Health (NZ) — specific customers not detailed in sources reviewed | NZ |
Strategy
Stated strategy (themes from FY25/FY26 reporting and the September 2025 roadshow)
Management's stated strategy rests on the following themes (paraphrased from the FY26 results release, FY25 results and AGM/roadshow summaries):
-
Sustainable growth through long-term, contracted recurring revenue — prioritising multi-year enterprise contracts and ARR growth over one-off revenue.
-
Organic expansion in established markets — "land and expand": deploying additional Miya modules into existing customers (e.g., Miya Emergency at Hywel Dda and South Tees; Smartpage non-clinical at NCIC; additional beds at Western Health).
-
Conversion of the NHS installed base to full EPR — from South Tees to North Cumbria to UH Sussex, Alcidion is positioning as the modular EPR alternative for trusts that do not want single-vendor lock-in.
-
Patient flow leadership — management cites an 18% compound growth forecast for the global patient-flow market to 2034 and positions Alcidion as an industry leader; Kyra was explicitly framed as executing this priority.
-
Product evolution with AI — Miya AI Service and the SaMD-registered Concept Detection capability.
-
New territories and adjacencies — Canada and the Middle East; aged care.
-
Disciplined M&A — with a growing cash position, brokers (Canaccord) see bolt-on acquisitions becoming more tangible; Kyra was the first deal in 4.5 years.
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Status / targets |
|---|---|---|---|
| Cost restructure | Q3 FY24 | Headcount and cost reduction; A$1.0M one-off cost | Completed; ≈A$3.35M half-yearly employee-cost saving (H1 FY25 vs H1 FY24) |
| North Cumbria EPR | Feb 2025 | Second full EPR; 10 years | Phase 1 go-live Q4 FY26, on time; TCV now ≈A$50M |
| Wales market entry | Feb 2025 | Hywel Dda (Miya Flow, Observations, Smartpage) | Implemented FY26; expanded with Miya Emergency |
| South Australia entry | Oct 2024 | NALHN (first SA Miya Precision) | Implemented FY26 |
| Growth strategy roadshow | Sep 2025 | Articulated organic, AI, new-territory and adjacency strategy | — |
| Leidos/ADF expansion | Nov 2025 | Third expansion, A$12.3M TCV | Leidos ARR ≈A$6.1M; potential lifetime value ≈A$100M |
| AI medical-device registration | Feb 2026 | Concept Detection Class I SaMD (Australia and UK) | Commercially available as optional module |
| Queensland entry | Q3 FY26 | Gold Coast Health remote patient monitoring (5 years) | Live by Aug 2026 |
| UH Sussex EPR | May 2026 | Third EPR; first NHS EPR including Virtual Care | Phased go-live from spring 2027; full implementation ~2 years |
| Kyra acquisition | May–Jun 2026 | Patient flow consolidation in ANZ | Completed 29 Jun 2026; earn-out up to A$1.0M |
| Reduced reporting burden | Sep 2026 | ASX relief from quarterly 4C reporting | Next periodic report: H1 FY27 Appendix 4D by 28 Feb 2027 |
ESG/sustainability commitments: none quantified in the sources reviewed. Cost programmes with targets: no current programme announced; FY26 salaries rose only 3% with a steady staff base.
Management guidance and medium-term targets
| Guidance item | Detail | Source |
|---|---|---|
| FY27 revenue | Expected to exceed FY26 (A$51.6M) | FY26 results |
| FY27 Underlying EBITDA | Expected to exceed FY26 (A$6.8M) | FY26 results |
| FY27 contracted revenue (start of year) | A$44.9M (+32%), including A$38.3M ARR | FY26 results |
| FY27 gross margin | Return to mid-80% range | FY26 results |
| FY27 EBITDA/operating cash flow | Contracted base provides visibility over a positive result before new sales | FY26 results |
| Long-term contracted revenue | ≈A$140M of contracted revenue to be recognised out to 2030 (stated at FY25, before UH Sussex and FY26 expansions) | FY25 results |
| Medium-term numerical targets (e.g., margin or revenue targets beyond FY27) | — | — |
Products & Services
Because Alcidion reports a single segment, the catalog is organised by product family. Pricing is not publicly disclosed for any product; contracts are typically priced as multi-year total contract value (TCV) combining upfront licence, implementation services and annual support/subscription fees.
Miya Precision platform (flagship)
| Product / module | Description and capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Miya Precision (platform) | Cloud-native, modular clinical platform aggregating real-time data from multiple hospital systems into a longitudinal record; interoperability engine; dashboards; clinical decision support | Public hospitals and health systems | Platform evolution of original Miya; NT Health upgrade from earlier Miya version disclosed FY22 | Live in >400 hospitals / 87 organisations (company, 2025) |
| Miya Precision EPR | Full electronic patient record configuration combining Miya modules with Silverlink PCS PAS and partner products | Mid-to-large NHS trusts | First EPR: South Tees (extended to 2033); NCIC (Feb 2025); UH Sussex (May 2026) | Three UK EPR contracts; NCIC Phase 1 go-live Q4 FY26 |
| Miya Flow | Enterprise patient flow and bed management — real-time view of patient journey, capacity and discharge | Acute hospitals, community trusts | Deployed Alfred Health (3 campuses), Bolton (replacing ExtraMed), Herefordshire & Worcestershire, Hywel Dda | Company describes itself as an industry leader in patient flow |
| Miya Access | Access/capacity visibility module (deployed with Flow and Command) | Acute hospitals | Alfred Health go-live (FY23) | — |
| Miya Command | Command-centre view of hospital operations | Large health services | Alfred Health (FY23); Western Health expansion (Q4 FY26) | — |
| Miya Noting | Structured and free-text clinical documentation | EPR and module customers | South Tees rollout (FY23) | Host module for Concept Detection |
| Miya Concept Detection (AI) | AI-assisted feature within Miya Noting that reads free-text clinician notes, identifies medical concepts and suggests standard codes for clinician review | Existing Miya customers; new EPR customers | Registered Class I SaMD in Australia (ARTG) and UK (MHRA), announced 19 Feb 2026 | Sold as an optional module |
| Miya AI Service | Proprietary secure architecture for deploying AI capabilities inside Miya Precision | Miya customers | Announced Feb 2026 | Foundation for future AI features |
| Miya Observations & Assessments (formerly Patientrack) | Digital vital-signs capture, early-warning scores (e.g., NEWS2), nursing assessments | Acute hospitals | Acquired Jul 2018; already live at UH Sussex prior to EPR award | Renewals reported Q3 FY26 |
| Miya Emergency (Miya ED) | ED-specific module for fast-paced emergency workflows | Acute trusts | Expansions at Hywel Dda and South Tees (Q3 FY26) | Optional module in UH Sussex contract |
| Miya Virtual Care / Remote Patient Monitoring | Hospital-in-the-home and remote monitoring | Health services expanding virtual care | Sydney LHD (FY22); Gold Coast Health 5-yr contract (Q3 FY26, live by Aug 2026); UH Sussex is the first NHS trust to include Virtual Care in an EPR | — |
| Smartpage | Clinical communications and task management (replacing pagers); expanded to non-clinical communications | Acute hospitals | Lancashire Teaching (company reports at least 2 hours saved per 12-hour shift); NCIC clinical then non-clinical (FY26) | — |
Patient administration
| Product | Description | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Silverlink PCS (PAS) | Patient Administration System — registration, scheduling, admissions/discharges/transfers, waiting lists; integrates with other clinical systems | NHS trusts | Acquired Dec 2021; renewals at Moorfields Eye, Liverpool Heart & Chest, Royal Wolverhampton | One of the last independent specialist PAS vendors in the NHS market |
Kyra flow products (acquired 29 June 2026)
| Product | Description | Target customer | Notes |
|---|---|---|---|
| Kyra Patient Flow Manager | Real-time oversight of inpatient journey from admission to discharge; bed management | Queensland HHSs (majority), Vic/WA/Tas public and private hospitals | ≈33 customers; top-10 customers average ≈10-year tenure |
| Kyra Queue Manager | Outpatient check-in, queuing, wayfinding and appointment flow | Outpatient departments | — |
| Kyra IQ | Data consolidation, referral management, triage and operational reporting | Health service operations | — |
FY26 (pro forma) revenue ≈A$3.7M with >90% recurring; ARR ≈A$3.6M at 30 June 2026 (acquisition announcement 18 May 2026; FY26 results).
Legacy and services
| Offering | Description | Notes |
|---|---|---|
| ExtraMed | UK patient-flow software acquired Apr 2021 | Being migrated to Miya Flow (e.g., Bolton FY23); contributed the Herefordshire & Worcestershire win |
| Technical services (MKM Health heritage) | Systems integration, health-data analytics, real-time data replication | Supports implementation revenue |
| Hosting | Hosted/cloud delivery of Miya Precision | Included in recurring revenue definition |
| Third-party partner products (prime contracting) | e.g., Mizaic MediViewer EDMS at NCIC; third-party licences in UH Sussex scope | Lower gross margin; drove FY26 gross margin to 80.3% |
Financial Narrative
Sources: S&P Global Market Intelligence (via StockAnalysis.com) for statutory line items FY2022–FY2026; company results releases for underlying EBITDA, ARR and commentary. All AUD millions unless otherwise labelled.
Income statement
Notes: Company-reported EBITDA: FY22 −A$1.6M and FY23 −A$1.5M (FY23 release); FY24 −A$4.545M and FY25 A$4.843M (FY25 release); FY26 A$6.2M (FY26 release summary). The S&P series differs because it treats FX gains/losses, share-based payments and certain one-offs differently. EPS is derived from NPAT ÷ weighted shares; the FY26 release reports NPAT A$2.3M, +38%. Tax line sign convention: S&P shows negative "income tax expense" (i.e., a benefit) in FY23–FY26.
Underlying EBITDA (company measure: EBITDA excluding restructure costs and share-based payments)
Source: FY25 and FY26 results releases. Margin derived.
Margins
Revenue CAGR: FY2022→FY2026 (4 years) ≈10.7% p.a.; FY2021 (A$25.88M) → FY2026 (5 years) ≈14.8% p.a. (derived from S&P revenue series).
Commentary — income statement. The five-year record divides into three phases. Phase 1 (FY22–FY23): acquisitive growth with cost build. Revenue rose 33% in FY22 and 18% in FY23, boosted by the Silverlink and ExtraMed acquisitions, but SG&A grew faster (salaries +27% in FY23 per the FY23 release, reflecting Silverlink staff, H2 FY22 hires and ~10 extra roles in cyber security and product support) as management staffed for a UK EPR procurement wave that then slipped. Phase 2 (FY24): the trough. Revenue fell 8% to A$37.1M as Alcidion's portion of the Leidos/ADF implementation neared completion and an Australian third-party contract was restructured from prime to subcontract; NPAT was −A$8.4M. Management executed a cost restructure in Q3 FY24 (A$1.0M one-off cost), and the FY25 H1 results show a A$3.35M half-on-half reduction in employee benefits expense. Phase 3 (FY25–FY26): operating leverage. With the cost base reset and NHS EPR wins (North Cumbria, then UH Sussex) converting, revenue grew 10% then 27%, SG&A rose only 6% in FY26, and EBIT turned positive (A$2.55M) for the first time in the period. The FY26 gross margin dip (80.3% vs 88.2%) is attributable to third-party product revenue under prime-contract arrangements; management guides to a return to the mid-80% range in FY27.
Balance sheet
Note: Alcidion has no bank borrowings; the only "debt" is AASB 16 lease liabilities. The company consistently describes itself as having "no debt."
Commentary — balance sheet. Goodwill and intangibles (A$91.1M) constitute ~75% of total assets, a legacy of the MKM/Patientrack (2018), ExtraMed (2021) and Silverlink (2021) acquisitions; tangible book value is approximately nil (−A$0.18M at FY26 per S&P). No goodwill impairment has been recorded in the period, which the FY25–FY26 earnings recovery and the UK EPR wins support. Intangibles amortise at ≈A$1.4–1.5M per year (S&P "other amortization"). Cash troughed at A$7.7M at 31 December 2024 (H1 FY25 release) — the low point of the cycle — before recovering to A$20.6M at June 2026 despite the A$1.5M net Kyra completion payment. Unearned revenue of ≈A$14–15M (invoiced in advance) is a structural feature that funds working capital: Alcidion bills annual support in advance, and H2 (particularly Q4) is the seasonal peak for cash collection.
Cash flow
Notes: FY23 acquisition outflow (A$2.69M) is understood to relate to deferred/contingent Silverlink consideration (FY22 presentation references a second Silverlink tranche); FY26 outflow is the A$1.5M net Kyra completion payment (A$3.0M upfront less completion adjustments). Company-reported FY26 operating cash flow: A$6.8M, +19%, representing ~100% conversion of Underlying EBITDA.
Commentary — cash flow. Alcidion is a capital-light business (capex <1% of revenue) because development costs are expensed, so operating cash flow ≈ free cash flow. The FY24 outflow (−A$7.1M) reflected both losses and an adverse H1 seasonal pattern; H2 FY24 operating cash flow was already positive (+A$4.3M). FY26 cash generation was flattered by a large Q4 receipt (A$24.6M quarterly receipts including a A$10.6M UH Sussex upfront licence payment, Q4 FY26 4C), partly offset by A$4.1M of product costs for third-party licences in that quarter. Full-year FY26 cash receipts were A$56.1M.
Ratios
Other ratios (FY26 / TTM, S&P Global unless stated): ROIC 1.76%; ROCE 2.62%; interest coverage ≈44.8x (EBIT ÷ lease interest); net debt/EBITDA not meaningful (net cash of A$19.8M ≈ 2.9x Underlying EBITDA); cash conversion cycle not meaningful for a software business with no inventory and customer prepayments (effectively negative working-capital cycle given unearned revenue exceeds receivables).
Commentary — ratios. Returns remain thin (ROE ≈2.5%) because ≈A$91M of acquired goodwill and intangibles sits in the equity base while earnings have only just turned positive. The improving trajectory is the point: if Underlying EBITDA of A$6.8M grows as guided and intangible amortisation steadily declines, ROE could reach high single digits without any balance-sheet change. Liquidity has strengthened (current ratio 1.22x), and the negative working-capital profile is a structural strength.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Origin |
|---|---|---|
Alcidion Group Limited | Australia | Listed parent |
Alcidion Corporation Pty Ltd | Australia | Founding operating company |
MKM Health Pty Ltd | Australia | Acquired 3 Jul 2018 |
MKM Health (NZ) Ltd | New Zealand | Acquired 3 Jul 2018 |
Patientrack Holdings Ltd; Patientrack (UK) Ltd; Patientrack Pty Ltd | UK / Australia | Acquired 3 Jul 2018 |
MKM Consulting (UK) Ltd | UK | Dormant; acquired with Patientrack |
ExtraMed (UK entity) | UK | — |
Silverlink PCS Software Ltd | UK | Acquired Dec 2021 |
Kyra flow business and assets | Australia | Asset acquisition completed 29 Jun 2026 (no entity acquired) |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Recurring product revenue (AUD Mn) | 26.2 | 26.0 | 31.9 |
Non-recurring revenue, derived (AUD Mn) | 10.9 | 14.8 | 19.7 |
Total revenue (AUD Mn) | 37.1 | 40.8 | 51.6 |
Recurring share of revenue (%) | 70.7 | 63.7 | 61.8 |
Recurring YoY growth (%) | — | -0.9 | 22.7 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ARR at 30 June (AUD Mn) | 21.8 | 28.5 | 38.3 |
ARR YoY growth (%) | — | 31 | 34 |
Revenue by Segment
| Metric | FY2024 | FY2025 | FY2026 | FY2027 |
|---|---|---|---|---|
Contracted (sold + renewal) revenue for the year, at start of year (AUD Mn) | 33.7 | 28.0 | 34.0 | 44.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 34.36 | 40.40 | 37.06 | 40.79 | 51.64 |
Revenue growth (%) | 32.7 | 17.6 | -8.3 | 10.1 | 26.6 |
Cost of revenue (AUD Mn) | 4.86 | 5.63 | 5.14 | 4.80 | 10.18 |
Gross profit (AUD Mn) | 29.49 | 34.77 | 31.92 | 35.99 | 41.46 |
SG&A (AUD Mn) | 25.62 | 32.15 | 31.26 | 28.18 | 29.75 |
Operating income / EBIT (AUD Mn) | -1.73 | -4.73 | -7.68 | -0.56 | 2.55 |
EBITDA, S&P definition (AUD Mn) | -0.65 | -3.73 | -5.77 | 1.94 | 5.34 |
EBITDA, company-reported (AUD Mn) | -1.6 | -1.5 | -4.5 | 4.8 | 6.2 |
Restructuring / M&A charges (AUD Mn) | 2.14 | 0.00 | 1.03 | 0.12 | 0.41 |
Pre-tax income (AUD Mn) | -3.91 | -4.74 | -8.70 | 0.32 | 1.32 |
Income tax benefit (+) / expense (-) (AUD Mn) | -0.50 | 1.12 | 0.28 | 1.33 | 0.97 |
Net income / NPAT (AUD Mn) | -4.41 | -3.62 | -8.42 | 1.65 | 2.29 |
Weighted shares, basic (M) | 1,164 | 1,268 | 1,316 | 1,343 | 1,343 |
EPS basic, derived (AUD cents) | -0.38 | -0.29 | -0.64 | 0.12 | 0.17 |
EPS diluted, derived (AUD cents) | -0.38 | -0.29 | -0.64 | 0.12 | 0.17 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2024–FY2026)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Underlying EBITDA (AUD Mn) | -3.4 | 5.1 | 6.8 |
Underlying EBITDA margin (%) | -9.1 | 12.5 | 13.2 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 85.8 | 86.1 | 86.1 | 88.2 | 80.3 |
Operating (EBIT) margin (%) | -5.0 | -11.7 | -20.7 | -1.4 | 4.9 |
EBITDA margin, S&P (%) | -1.9 | -9.2 | -15.6 | 4.8 | 10.3 |
Net margin (%) | -12.8 | -9.0 | -22.7 | 4.0 | 4.4 |
Balance Sheet and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 128.35 | 120.68 | 114.46 | 115.63 | 121.88 |
Cash and equivalents (AUD Mn) | 17.34 | 14.64 | 11.80 | 17.70 | 20.64 |
Accounts receivable (AUD Mn) | 7.25 | 3.30 | 3.55 | 3.68 | 5.24 |
Goodwill (AUD Mn) | 67.76 | 67.76 | 67.76 | 67.76 | 68.68 |
Other intangibles (AUD Mn) | 31.06 | 29.07 | 26.19 | 22.59 | 22.37 |
Goodwill + intangibles (AUD Mn) | 98.82 | 96.83 | 93.95 | 90.35 | 91.05 |
Short-term debt — current lease liabilities (AUD Mn) | 0.62 | 0.69 | 0.70 | 0.71 | 0.53 |
Long-term debt — non-current lease liabilities (AUD Mn) | 1.87 | 1.46 | 1.00 | 0.69 | 0.28 |
Total debt incl. leases (AUD Mn) | 2.48 | 2.16 | 1.70 | 1.41 | 0.81 |
Net cash (AUD Mn) | 14.86 | 12.49 | 10.10 | 16.29 | 19.83 |
Current unearned revenue (AUD Mn) | 12.91 | 11.61 | 12.83 | 15.04 | 14.41 |
Total liabilities (AUD Mn) | 34.40 | 30.52 | 27.52 | 27.83 | 31.01 |
Shareholders' equity (AUD Mn) | 93.96 | 90.17 | 86.94 | 87.80 | 90.87 |
Working capital (AUD Mn) | 1.87 | -0.30 | -0.67 | 2.83 | 5.28 |
Shares outstanding, period end (M) | 1,268 | 1,268 | 1,342 | 1,343 | 1,344 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | 1.00 | 0.17 | -7.13 | 5.76 | 6.85 |
Capital expenditure (AUD Mn) | -0.31 | -0.45 | -0.05 | -0.13 | -0.23 |
Free cash flow (AUD Mn) | 0.69 | -0.29 | -7.18 | 5.64 | 6.62 |
Free cash flow margin (%) | 2.0 | -0.7 | -19.4 | 13.8 | 12.8 |
Cash acquisitions (AUD Mn) | -59.43 | -2.69 | 0.00 | 0.00 | -1.48 |
Equity issued (AUD Mn) | 51.94 | 0.00 | 5.40 | 0.00 | 0.00 |
Lease principal repaid (AUD Mn) | -0.61 | -0.62 | -0.66 | -0.76 | -0.80 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on closing equity, derived (%) | -4.7 | -4.0 | -9.7 | 1.9 | 2.5 |
ROA on closing assets, derived (%) | -3.4 | -3.0 | -7.4 | 1.4 | 1.9 |
Current ratio (x) | 1.08 | 0.99 | 0.97 | 1.14 | 1.22 |
Debt (leases) to equity (x) | 0.026 | 0.024 | 0.020 | 0.016 | 0.009 |
Asset turnover, derived (x) | 0.27 | 0.33 | 0.32 | 0.35 | 0.42 |
Days sales outstanding, derived (days) | 77 | 30 | 35 | 33 | 37 |
Unearned revenue / revenue (%) | 37.6 | 28.7 | 34.6 | 36.9 | 27.9 |
Revenue by Region (%) and Revenue by Region
| Metric | FY2025 | FY2026 |
|---|---|---|
UK share of revenue (%) | 63 | 63 |
ANZ share of revenue (%) | 37 | 37 |
UK revenue, derived (AUD Mn) | 25.7 | 32.5 |
ANZ revenue, derived (AUD Mn) | 15.1 | 19.1 |
UK revenue growth, derived (%) | — | 26.5 |
ANZ revenue growth, derived (%) | — | 26.5 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Share price | A$0.105 | S&P Global via StockAnalysis |
Market capitalisation | A$141.1M | S&P Global |
Enterprise value | A$121.3M | S&P Global |
52-week price change | +12.9% | S&P Global |
50-day / 200-day moving average | A$0.10 / A$0.10 | S&P Global |
Beta (5-year) | 1.03 | S&P Global |
Average volume (20 days) | ≈538,000 shares | S&P Global |
P/E (trailing) | 58.8x | S&P Global |
P/E (forward) | 48.1x | S&P Global |
EV/Sales (FY26) | 2.22x | S&P Global |
EV/EBITDA (S&P EBITDA) | 18.9x | S&P Global |
EV/Underlying EBITDA (A$6.8M), derived | 17.8x | Derived |
EV/ARR (A$38.3M), derived | 3.2x | Derived |
P/B | 1.48x | S&P Global |
FCF yield | 4.9% | S&P Global |
Capital Markets Data (AUD)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
52-week low before annual report date (AUD) | 0.105 | 0.092 | 0.044 | 0.049 | 0.088 |
52-week high before annual report date (AUD) | 0.397 | 0.175 | 0.125 | 0.110 | 0.140 |
Analyst Ratings & Targets
| Broker | Date | Rating | Target (AUD) | Notes |
|---|---|---|---|---|
Bell Potter (Thomas Wakim) | 15 Jan 2026 | Buy | 0.17 (from 0.15) | FY26/FY27/FY28 revenue forecasts A$52.6M / A$56.4M / A$61.0M |
Canaccord Genuity | 2026 | — | — | Highlighted execution on UH Sussex and potential acquisitions |
Consensus (S&P Global, 4 analysts) | Oct 2026 | Buy | 0.15 (+43% vs A$0.105) | 3-year revenue growth forecast ≈11% p.a.; 3-year EPS growth ≈34% p.a. |
Capital Markets
| Item | Status |
|---|---|
Dividend history | No dividends paid FY22–FY26; S&P lists no current dividend. (A German aggregator lists a 2022 distribution; which is not corroborated by S&P cash-flow data showing nil dividends paid) |
Dividend policy | Not publicly disclosed; cash retained for growth and M&A |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | Lease liabilities only: A$0.53M current, A$0.28M non-current (30 June 2026) |
Analyst Conclusions
Management guidance (FY27)
Revenue and Underlying EBITDA are expected to exceed FY26 levels (A$51.6M and A$6.8M respectively); the year begins with record contracted revenue of A$44.9M, including A$38.3M ARR; gross margin is expected to recover to the mid-80% range; and management states the contracted base alone gives visibility over positive EBITDA and operating cash flow before new FY27 sales (FY26 results, 19 August 2026).
Consensus expectations
Bell Potter (January 2026) forecast FY27 revenue of A$56.4M and FY28 of A$61.0M; S&P Global consensus implies ≈11% annual revenue growth over three years and ≈34% EPS growth. The mechanical challenge for FY27 is replacing ≈A$8.5M of one-off UH Sussex licence revenue recognised in FY26 with recurring fees (UH Sussex recurring revenue, a full year of Kyra at ≈A$3.6–3.7M, and Leidos/NCIC expansions).
Bull case
-
ARR compounding plus Kyra: ARR has grown 31% and 34% in consecutive years; Kyra adds ≈A$3.6M of >90% recurring revenue bought at ≈2.7x EBITDA, and UH Sussex recurring fees start in FY27 — supporting ARR well above A$40M within FY27.
-
EPR credibility flywheel: three NHS EPR wins in roughly three years, with NCIC delivered on time, make Alcidion a credible shortlist vendor for every mid-sized trust EPR tender.
-
Valuation versus cash generation: EV of ≈A$121M equals ≈3.2x ARR and ≈18x Underlying EBITDA for a business growing ARR >30% with net cash and ≈100% EBITDA-to-cash conversion; operating leverage (salaries +3% vs revenue +27%) should expand margins further.
Bear case
-
FY27 revenue air-pocket: FY26 included ≈A$8.5M of non-recurring UH Sussex licence revenue plus implementation and third-party revenue; if new upfront deals do not land, headline growth could slow sharply even as ARR rises.
-
Execution concentration: with ≈140 staff, simultaneous delivery of NCIC later phases, UH Sussex (go-live from spring 2027) and Leidos expansions creates single-point-of-failure risk; a troubled go-live would damage the reference pipeline.
-
Low returns and dilution history: ROE ≈2.5%, goodwill-heavy balance sheet, and equity raises in FY22 and FY24; further M&A could again require equity if larger targets emerge.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| 2026 AGM — trading commentary and any FY27 guidance refinement | Oct–Nov 2026 |
| New NHS EPR or major module contract wins | Ongoing |
| Kyra integration and earn-out outcome (12-month recurring-revenue test) | By ≈Jun 2027 |
| Cross-sell of Miya Precision into Kyra/Queensland customers | FY27 |
| UH Sussex readiness milestones ahead of phased go-live | Through spring 2027 |
| NCIC subsequent phase go-lives | FY27 |
| H1 FY27 results (Appendix 4D) — first test of gross-margin recovery and ARR | By 28 Feb 2027 |
| Further bolt-on M&A using A$20.6M cash | Opportunistic |
| Commercial uptake of Concept Detection / Miya AI Service | FY27 |
| Progress in new territories (Canada, Middle East) or aged care | Longer-dated |
Concluding analyst verdict
Alcidion has completed the most important transition in its 25-year history: from a cash-hungry, acquisitive module vendor that lost A$8.4M in FY24 to a self-funding, profitable platform company with A$38.3M of ARR, A$6.8M of Underlying EBITDA and A$20.6M of net cash two years later. The evidence for the turnaround is not merely financial. Three competitively tendered NHS EPR contracts, an on-time Phase 1 go-live at North Cumbria, four expansions at the Australian Defence Force and a disciplined, low-multiple consolidation of Telstra Health's Kyra products together suggest a business whose modular, interoperable proposition has found product-market fit with mid-sized public health systems.
The investment debate is now about durability and scale rather than survival. The FY26 result was flattered by a large upfront licence and third-party pass-through revenue, so FY27 headline growth will be modest unless new contracts land; the cleaner metric is ARR, where management's starting position (A$44.9M contracted, +32%) is strong. Execution risk is the principal concern: a 140-person company is simultaneously delivering several of the most complex software implementations in healthcare, and its reputation — and therefore its pipeline — depends on each one going live well. Concentration in a handful of customers and the goodwill-heavy balance sheet keep statutory returns low for now.
At roughly 3x ARR and under 18x Underlying EBITDA, with net cash and near-total cash conversion, the market appears to price Alcidion as a steady micro-cap rather than a business compounding recurring revenue above 30%. If FY27 delivers ARR above A$45M, gross margin back in the mid-80s and at least one further EPR or major module win, the case for a re-rating towards broker targets (A$0.15–0.17) is credible. The balance of evidence supports a constructive view, conditioned on monitoring UH Sussex readiness and Kyra integration closely, and recognising that reduced reporting frequency from FY27 will make interim monitoring harder.
APPENDIX — SOURCE REGISTER
-
ASX: FY26 Full Year Results release (Alcidion) — announcements.asx.com.au/asxpdf/20260819/pdf/072x6kdhwcr1d4.pdf — 19 Aug 2026 — FY26 financials, ARR, contracts, Kyra, outlook, headcount
-
ASX: Q4 FY26 Quarterly Activities Report — announcements.asx.com.au/asxpdf/20260723/pdf/071z7fnh1b6f8t.pdf — 23 Jul 2026 — Cash flow, Q4 TCV, Kyra payment
-
ASX: FY26 trading update — announcements.asx.com.au/asxpdf/20260629/pdf/0713dqlcc8xq7s.pdf — 29 Jun 2026 — Kyra completion
-
ASX: UH Sussex contract — announcements.asx.com.au/asxpdf/20260525/pdf/06zxjp8140vbrr.pdf — 25 May 2026 — UH Sussex terms
-
ASX: Kyra acquisition — announcements.asx.com.au/asxpdf/20260518/pdf/06zp94b3v05k8y.pdf — 18 May 2026 — Kyra deal
-
ASX: Q3 FY26 4C — announcements.asx.com.au/asxpdf/20260429/pdf/06yz2ypw46c3pn.pdf — 29 Apr 2026 — Q3 FY26
-
ASX: H1 FY26 Results — announcements.asx.com.au/asxpdf/20260226/pdf/06wrxgdf6gvjpx.pdf — 26 Feb 2026 — H1 FY26
-
ASX: SaMD registration — announcements.asx.com.au/asxpdf/20260219/pdf/06whcyy4qvwl28.pdf — 19 Feb 2026 — AI regulatory
-
ASX: Form 604 — announcements.asx.com.au/asxpdf/20260119/pdf/06vdbkdcf4gtx0.pdf — 19 Jan 2026 — Substantial holder
-
ASX: ASX 4C relief — investorpa.com/announcement-pdf/20260903/338309.pdf — 3 Sep 2026 — Reporting relief, address
-
ASX: FY25 Full Year Results — announcements.asx.com.au/asxpdf/20250828/pdf/06ng58pgg8mfy9.pdf — 28 Aug 2025 — FY24–FY25 data
-
ASX: H1 FY25 Results — announcements.asx.com.au/asxpdf/20250227/pdf/06g0kr3jv8f03q.pdf — 27 Feb 2025 — H1 FY25
-
ASX: Q3 FY25 4C — announcements.asx.com.au/asxpdf/20250422/pdf/06hxltgt2skh8t.pdf — 22 Apr 2025 — NCIC/Hywel Dda
-
ASX: FY24 Full Year Results — announcements.asx.com.au/asxpdf/20240829/pdf/0676qqlkdb5xlt.pdf — 29 Aug 2024 — FY24
-
ASX: FY23 Full Year Results — announcements.asx.com.au/asxpdf/20230824/pdf/05t03g1bnr0csy.pdf — 24 Aug 2023 — FY23
-
ASX: FY22 results presentation — announcements.asx.com.au/asxpdf/20220830/pdf/45dgpncwd11qp0.pdf — 30 Aug 2022 — Silverlink, board changes
-
ASX: FY19 Annual Report — announcements.asx.com.au/asxpdf/20190829/pdf/447zwdj35vf9mh.pdf — 29 Aug 2019 — MKM/Patientrack
-
S&P Global via StockAnalysis.com (income statement, balance sheet, cash flow, statistics) — Updated to 6 Oct 2026 — Five-year financials, market data
-
Bell Potter research — bellpotter.com.au/wp-content/uploads/2026/01/ALC-20260115.pdf — 15 Jan 2026 — Rating, forecasts
-
FNArena ALC page — 2026 — Broker commentary (Bell Potter, Canaccord)
-
Quartr event summaries (FY26, Q4 FY26, AGM 2025) — 2026 — AGM, board changes, geographic split
-
Digital Health (digitalhealth.net) — Silverlink 2021; UH Sussex Jan and Jun 2026 — 2021–2026 — Deal values, UH Sussex
-
TechMarketView — 26 Jun 2026 — UH Sussex context, Hywel Dda
-
SmallCaps; MT Newswires; Nelson Advisors; HINZ — May–Jul 2026 — Kyra terms and context
-
Lawyers Weekly; Oaklins — 2021 — Silverlink value, advisers
-
MarketScreener / MarketIndex / TipRanks / Simply Wall St — 2025–2026 — Director profiles, shareholdings
-
StockLight — 2016–2026 — Announcement history, annual-report trading ranges
-
CB Insights — — — Listing date, PIPE, deal dates
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background |
|---|---|---|---|
Kate Quirke | Group Managing Director & CEO | CEO since 3 Jul 2018; later appointed MD | CEO of MKM Health (acquired by Alcidion, 2018) |
Matthew Gepp | Chief Financial Officer | In role since at least Aug 2023 (hosted FY23 results webcast) | — |
Dr Malcolm Pradhan | Co-founder (historically Chief Medical Officer / executive director) | Since 2000 | Clinician and health informatician |
Lynette Ousby | UK Managing Director (as at Dec 2021) | — | — |
Board of Directors
| Name | Role | Independence | Appointed | Background |
|---|---|---|---|---|
Rebecca Wilson | Non-Executive Chair | Independent (presumed) | NED Jul 2017; Chair 30 Aug 2019 | CEO of Buchan Consulting (since 2014); NED Hansen Technologies (2024), Vitura Health (2024); Chair Clever Culture Systems (2023); ~25-year executive career in communications, investor relations, capital management; Deakin University |
Kate Quirke | Group Managing Director & CEO | Executive | 2018 | See above |
Prof. Andrew Way AM | Non-Executive Director | Independent | 2025 (elected at Oct 2025 AGM) | 15+ years as CEO of Alfred Health; Chair of HealthShare Victoria; Adjunct Clinical Professor, Monash University; UK and Australian health-system leadership |
Daniel Sharp | Non-Executive Director | — | 1 Sep 2021 | — |
Victoria Weekes | Former NED and Audit & Risk Chair | — | Sep 2021 – retired Jun 2025 | Ex-Citigroup MD, Westpac EGM; NED Bendigo & Adelaide Bank; former Chair Sydney LHD |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
3 Jul 2018 | Kate Quirke becomes CEO; Ray Blight steps down | MKM Health/Patientrack acquisition |
1 Sep 2021 | Victoria Weekes and Daniel Sharp appointed NEDs | Board strengthening post-Silverlink |
17 Nov 2021 | Nick Dignam resigns | — |
Jun 2025 | Victoria Weekes retires | Board renewal |
| 2025 | Prof. Andrew Way AM appointed (elected Oct 2025) | Adds health-system CEO experience |
Major Shareholders
| Holder | Shares (M) | % of issued capital | As at | Source |
|---|---|---|---|---|
AustralianSuper Pty Ltd | 153.1 | 11.4 | 2025 (Simply Wall St data) | Aggregator; Jan 2026 substantial-holder changes may have altered this (see below) |
Dr Malcolm Pradhan (co-founder) | 134.6 | 10.0 | 2,025 | Simply Wall St |
Ray Blight (co-founder) | 68.7 | 5.11 | 25 Jul 2025 | MarketScreener |
Kate Quirke (MD & CEO) | ≈43.6 | ≈3.2 | Mar 2025 (after selling 5.0M shares) | ASX/TipRanks |
Rebecca Wilson (Chair) | 1.9 | 0.14 | 30 Jun 2025 | MarketScreener |
Victoria Weekes (former NED) | 0.4 | 0.03 | 30 May 2025 | MarketScreener |
Top 20 shareholders combined | — | 43.75 | Nov 2025 | Simply Wall St |
Competitive Landscape
Key Competitors
| Competitor | Ownership | Competes in | Relative positioning vs Alcidion |
|---|---|---|---|
Oracle Health (formerly Cerner) | Oracle Corp. (NYSE: ORCL) | Full EPR (UK, Australia) | Incumbent at many NHS trusts and Australian states; scale far larger; Alcidion often integrates with Cerner and markets itself as a modular alternative |
Epic Systems | Private (US) | Full EPR (large NHS trusts; select Australian health services) | Dominant in large academic centres; premium price and big-bang model — Alcidion targets trusts seeking lower cost/modularity |
Dedalus | Private (Ardian-backed) | EPR, PAS (UK, ANZ) | — |
System C (Careflow) | Private (UK) | EPR, PAS, patient flow, clinical communications (UK) | Direct UK modular competitor |
Nervecentre | Private (UK) | Observations, patient flow, clinical communications, EPR (UK) | Closest UK functional overlap with Patientrack/Smartpage/Miya Flow |
Altera Digital Health (Sunrise, Paragon) | Private (Harris/Constellation group) | EPR, PAS (UK, Australia) | Legacy PAS/EPR incumbent at NHS trusts |
MEDITECH | Private (US) | EPR (UK trusts, some Australian services) | Mid-market EPR competitor |
InterSystems (TrakCare) | Private (US) | EPR/PAS (Australia, UK) | State-wide PAS/EPR deployments in Australia |
TPP (SystmOne) | Private (UK) | Community/primary/integrated EPR (UK) | Community-care EPR competitor |
Telstra Health (pre-2026 for patient flow) | Telstra Group (ASX: TLS) | Patient flow (Kyra) — exited via sale to Alcidion | Competitor removed from ANZ patient-flow market by the Kyra deal |
Better (Better Meds / open platform) | Private | ePMA and clinical data platform (UK) | Adjacent; potential partner or competitor |
Peer Comparison FY2026
| Company | Latest revenue | Growth | Margins | Notes |
|---|---|---|---|---|
Alcidion (FY26) | A$51.6M | +27% | Gross 80.3%; Underlying EBITDA 13.2%; net 4.4% | Source: FY26 results |
Oracle Health | Not separately disclosed by Oracle | — | — | Cerner's last standalone revenue (CY2021) was ≈US$5.8B (pre-acquisition filings) |
Epic Systems | Private; press reports indicate annual revenue in the US$5–6B range | — | — | — |
Dedalus | Private; not publicly disclosed in sources reviewed | — | — | — |
System C, Nervecentre, Altera | Private | — | — | — |



